Spots Global Cancer Trial Database for tiragolumab
Every month we try and update this database with for tiragolumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck | NCT03708224 | Cancer Carcinoma Squamous Cell C... Head and Neck C... | Atezolizumab Tocilizumab Tiragolumab | 18 Years - | University of California, San Francisco | |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | NCT03869190 | Urothelial Carc... Bladder Cancer | Atezolizumab Enfortumab Vedo... Niraparib Magrolimab (Hu5... Tiragolumab Sacituzumab Gov... Tocilizumab Cisplatin Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer | NCT04300647 | Cervical Cancer | Tiragolumab Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC | NCT04958811 | Non-squamous No... | Tiragolumab Atezolizumab Bevacizumab | 18 Years - | Georgetown University | |
| A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) | NCT03337698 | Carcinoma, Non-... | Atezolizumab Cobimetinib RO6958688 Docetaxel CPI-444 Pemetrexed Carboplatin Gemcitabine Linagliptin Tocilizumab Ipatasertib Bevacizumab Sacituzumab Gov... Radiation Evolocumab Tiragolumab XL092 Camonsertib | 18 Years - | Hoffmann-La Roche | |
| A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) | NCT04513925 | Non-small Cell ... | Atezolizumab Tiragolumab Durvalumab | 18 Years - | Hoffmann-La Roche | |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | NCT03281369 | Gastric Adenoca... | 5-Fluorouracil ... Leucovorin Oxaliplatin Atezolizumab Cobimetinib Ramucirumab Paclitaxel PEGylated recom... BL-8040 Linagliptin Atezolizumab Cobimetinib Cisplatin Tiragolumab 5-Fluorouracil ... | 18 Years - | Hoffmann-La Roche | |
| A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer | NCT04619797 | Non-small Cell ... | Tiragolumab Atezolizumab Pemetrexed Carboplatin Cisplatin Tiragolumab Mat... Pembrolizumab | 18 Years - | Hoffmann-La Roche | |
| Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma | NCT06328036 | Recurrent Gliob... | Atezolizumab Biospecimen Col... Magnetic Resona... Surgical Proced... Tiragolumab | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer | NCT05009069 | Rectal Neoplasm... Rectal Cancer | Radiotherapy Capecitabine Fluorouracil Atezolizumab Tiragolumab | 18 Years - | Hoffmann-La Roche | |
| A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ) | NCT04933227 | Stomach Neoplas... Gastric Cancer Gastroesophagea... | Atezolizumab Tiragolumab Oxaliplatin Capecitabine | 18 Years - | Hoffmann-La Roche | |
| NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing | NCT05825625 | Non-small Cell ... | Atezolizumab Tiragolumab | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | NCT04543617 | Esophageal Squa... | Tiragolumab Atezolizumab Tiragolumab Mat... Atezolizumab Ma... | 18 Years - | Hoffmann-La Roche | |
| An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma | NCT05315713 | Non-Hodgkin Lym... | Mosunetuzumab S... Tiragolumab Atezolizumab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer | NCT05009069 | Rectal Neoplasm... Rectal Cancer | Radiotherapy Capecitabine Fluorouracil Atezolizumab Tiragolumab | 18 Years - | Hoffmann-La Roche | |
| Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors | NCT05483400 | Head and Neck N... MSI-H Cancer Melanoma | Tiragolumab and... | 18 Years - | University Medical Center Groningen | |
| A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response | NCT04632992 | Advanced Unrese... | Entrectinib Inavolisib Alectinib Ipatasertib Atezolizumab Trastuzumab Emt... Pertuzumab, Tra... Tucatinib Investigator's ... Paclitaxel Tiragolumab Pralsetinib | 18 Years - | Genentech, Inc. | |
| A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma | NCT05908786 | Carcinoma, Hepa... | Atezolizumab Bevacizumab Tiragolumab Tobemstomig | 18 Years - | Hoffmann-La Roche | |
| Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer | NCT04665856 | Small Cell Lung... | Tiragolumab Atezolizumab Carboplatin Etoposide Tiragolumab Mat... | 18 Years - | Hoffmann-La Roche | |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | NCT04486352 | Endometrial Can... | Atezolizumab - ... Bevacizumab Ipatasertib Talazoparib Trastuzumab emt... Tiragolumab Atezolizumab - ... Inavolisib Letrozole Giredestrant Abemaciclib | 18 Years - | Alliance Foundation Trials, LLC. | |
| Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma | NCT03784326 | Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... | Atezolizumab Conventional Su... Fluorouracil Oxaliplatin Tiragolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). | NCT05681039 | Squamous Cell C... Oral Cavity Squ... | Tiragolumab Atezolizumab Standard of Car... Questionnaires Cisplatin Carboplatin | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma | NCT04540211 | Esophageal Canc... | Atezolizumab Tiragolumab Paclitaxel Cisplatin Atezolizumab Ma... Tiragolumab Mat... | 18 Years - | Hoffmann-La Roche | |
| A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer | NCT04256421 | Small Cell Lung... | Tiragolumab Atezolizumab Carboplatin Etoposide Placebo | 18 Years - | Hoffmann-La Roche | |
| A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer | NCT04308785 | Carcinoma, Smal... | Atezolizumab Tiragolumab Placebo | 18 Years - | Hoffmann-La Roche | |
| NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing | NCT05825625 | Non-small Cell ... | Atezolizumab Tiragolumab | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | NCT03869190 | Urothelial Carc... Bladder Cancer | Atezolizumab Enfortumab Vedo... Niraparib Magrolimab (Hu5... Tiragolumab Sacituzumab Gov... Tocilizumab Cisplatin Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma | NCT05315713 | Non-Hodgkin Lym... | Mosunetuzumab S... Tiragolumab Atezolizumab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma | NCT05394337 | Metastatic Mali... | Atezolizumab Tiragolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma | NCT03554083 | Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... | Atezolizumab Cobimetinib Tiragolumab Vemurafenib | 18 Years - | Mayo Clinic | |
| Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients | NCT05743504 | Locally Advance... | Tiragolumab | 20 Years - | National Taiwan University Hospital | |
| A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck | NCT04665843 | Squamous Cell C... | Atezolizumab Tiragolumab Placebo | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) | NCT05116202 | Melanoma | Nivolumab Ipilimumab RO7247669 2100 ... Atezolizumab Tiragolumab RO7247669 600 m... | 18 Years - | Hoffmann-La Roche | |
| Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients | NCT05743504 | Locally Advance... | Tiragolumab | 20 Years - | National Taiwan University Hospital | |
| A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma | NCT05805501 | Renal Cell Carc... | Tobemstomig Tiragolumab Pembrolizumab Axitinib | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer | NCT05645692 | Urothelial Canc... | Atezolizumab Tobemstomig Tiragolumab | 18 Years - | Hoffmann-La Roche | |
| A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) | NCT04513925 | Non-small Cell ... | Atezolizumab Tiragolumab Durvalumab | 18 Years - | Hoffmann-La Roche | |
| Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients | NCT05743504 | Locally Advance... | Tiragolumab | 20 Years - | National Taiwan University Hospital | |
| Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma | NCT05394337 | Metastatic Mali... | Atezolizumab Tiragolumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma | NCT05908786 | Carcinoma, Hepa... | Atezolizumab Bevacizumab Tiragolumab Tobemstomig | 18 Years - | Hoffmann-La Roche | |
| A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy | NCT06267001 | Non-small Cell ... | Atezolizumab Tiragolumab Placebo | 18 Years - | Hoffmann-La Roche | |
| A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) | NCT06331598 | Solid Tumors | Atezolizumab Tiragolumab | 18 Years - | Hoffmann-La Roche | |
| Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma | NCT06328036 | Recurrent Gliob... | Atezolizumab Biospecimen Col... Magnetic Resona... Surgical Proced... Tiragolumab | 18 Years - | National Cancer Institute (NCI) | |
| A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer | NCT05645692 | Urothelial Canc... | Atezolizumab Tobemstomig Tiragolumab | 18 Years - | Hoffmann-La Roche | |
| A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy | NCT06267001 | Non-small Cell ... | Atezolizumab Tiragolumab Placebo | 18 Years - | Hoffmann-La Roche | |
| A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma | NCT05805501 | Renal Cell Carc... | Tobemstomig Tiragolumab Pembrolizumab Axitinib | 18 Years - | Hoffmann-La Roche | |
| Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases | NCT05746481 | Non-small Cell ... | Tiragolumab Atezolizumab Pemetrexed Carboplatin | 18 Years - | University of Pittsburgh | |
| A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response | NCT04632992 | Advanced Unrese... | Entrectinib Inavolisib Alectinib Ipatasertib Atezolizumab Trastuzumab Emt... Pertuzumab, Tra... Tucatinib Investigator's ... Paclitaxel Tiragolumab Pralsetinib | 18 Years - | Genentech, Inc. | |
| A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) | NCT05459129 | Squamous Cell C... | Atezolizumab Tiragolumab Carboplatin Paclitaxel | 18 Years - | Hoffmann-La Roche | |
| A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer | NCT04584112 | Triple-Negative... | Tiragolumab Atezolizumab Nab-paclitaxel Tiragolumab Atezolizumab Nab-paclitaxel Carboplatin Doxorubicin Cyclophosphamid... Granulocyte col... Granulocyte-mac... | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) | NCT05459129 | Squamous Cell C... | Atezolizumab Tiragolumab Carboplatin Paclitaxel | 18 Years - | Hoffmann-La Roche | |
| An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma | NCT05251948 | Gastric and Gas... | Atezolizumab Capecitabine Oxaliplatin Tiragolumab | 18 Years - | Hoffmann-La Roche | |
| A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma | NCT05805501 | Renal Cell Carc... | Tobemstomig Tiragolumab Pembrolizumab Axitinib | 18 Years - | Hoffmann-La Roche | |
| A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma | NCT05805501 | Renal Cell Carc... | Tobemstomig Tiragolumab Pembrolizumab Axitinib | 18 Years - | Hoffmann-La Roche | |
| Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases | NCT05746481 | Non-small Cell ... | Tiragolumab Atezolizumab Pemetrexed Carboplatin | 18 Years - | University of Pittsburgh | |
| Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients | NCT05743504 | Locally Advance... | Tiragolumab | 20 Years - | National Taiwan University Hospital | |
| A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy | NCT06267001 | Non-small Cell ... | Atezolizumab Tiragolumab Placebo | 18 Years - | Hoffmann-La Roche | |
| A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study | NCT05862285 | Cancer | Ipatasertib Tiragolumab Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy | NCT06267001 | Non-small Cell ... | Atezolizumab Tiragolumab Placebo | 18 Years - | Hoffmann-La Roche |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
